Becker's Healthcare March 26, 2024
More than a year after the FDA yanked away authorization from Evusheld, a monoclonal antibody treatment for COVID-19, the agency granted emergency use authorization to a new COVID-19 preventive drug March 22.
The medication, Pemgarda, is a monoclonal antibody that targets the SARS-CoV-2 spike protein, and it is indicated for patients 12 and older. The authorization is not an approval, meaning the FDA greenlit the medicine “based on a reasonable belief that the product may be effective based on the best evidence available at the time,” its website says, “without waiting for all the information that would be needed for an FDA approval.”
Evusheld, the last authorized COVID-19 therapy, was pulled in January 2023 after being on the market...
Today's Sponsors
Today's Sponsor